• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD? Authors' reply.

作者信息

Moolla Ahmad, Tomlinson Jeremy W

机构信息

Oxford Centre for Diabetes Endocrinology & Metabolism (OCDEM), NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, UK.

出版信息

Aliment Pharmacol Ther. 2020 Jun;51(11):1205-1206. doi: 10.1111/apt.15756.

DOI:10.1111/apt.15756
PMID:32424931
Abstract
摘要

相似文献

1
Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD? Authors' reply.社论：基于尿液的代谢组学能否改善非酒精性脂肪性肝病晚期纤维化的诊断？作者回复。
Aliment Pharmacol Ther. 2020 Jun;51(11):1205-1206. doi: 10.1111/apt.15756.
2
Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD?社论：基于尿液的代谢组学能否改善非酒精性脂肪性肝病中晚期纤维化的诊断？
Aliment Pharmacol Ther. 2020 Jun;51(11):1204-1205. doi: 10.1111/apt.15744.
3
Editorial: re-thinking cardiovascular risk factors in NAFLD with advanced fibrosis? Authors' reply.社论：重新审视非酒精性脂肪性肝病合并晚期纤维化时的心血管危险因素？作者回复。
Aliment Pharmacol Ther. 2020 May;51(10):988-989. doi: 10.1111/apt.15696.
4
Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome.利用尿类固醇代谢组学对非酒精性脂肪性肝病进行准确的无创诊断和分期。
Aliment Pharmacol Ther. 2020 Jun;51(11):1188-1197. doi: 10.1111/apt.15710. Epub 2020 Apr 16.
5
Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study.将尿类固醇代谢组学转化为非酒精性脂肪性肝病（TrUSt-NAFLD）分期的潜力：一项多中心、前瞻性验证研究的研究方案。
BMJ Open. 2024 Jan 18;14(1):e074918. doi: 10.1136/bmjopen-2023-074918.
6
Editorial: "being normal weight each day keeps NAFLD and fibrosis away"-the importance of reducing cumulative exposure to overweight. Authors' reply.社论：“每日保持正常体重可预防非酒精性脂肪性肝病和肝纤维化”——减少超重累积暴露的重要性。作者回应。
Aliment Pharmacol Ther. 2023 May;57(10):1168-1169. doi: 10.1111/apt.17478.
7
Editorial: stepwise risk stratification for both F3 and F4 in NAFLD patients-authors' reply.编者按：非酒精性脂肪性肝病患者F3和F4的逐步风险分层——作者回复
Aliment Pharmacol Ther. 2018 Dec;48(11-12):1318-1319. doi: 10.1111/apt.15040.
8
Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression.胆汁酸谱、组织病理学指标和非酒精性脂肪性肝病进展的遗传变异。
Metabolism. 2021 Mar;116:154457. doi: 10.1016/j.metabol.2020.154457. Epub 2020 Dec 1.
9
Editorial: NAFLD in Asia-clinical associations with advanced disease become clearer. Authors' reply.社论：亚洲的非酒精性脂肪性肝病——与晚期疾病的临床关联日益明晰。作者回复。
Aliment Pharmacol Ther. 2018 Apr;47(7):1037-1038. doi: 10.1111/apt.14572.
10
Editorial: optimal combination of non-invasive tests to determine significant fibrosis in non-alcoholic fatty liver disease-authors' reply.
Aliment Pharmacol Ther. 2023 Jun;57(12):1463-1464. doi: 10.1111/apt.17517.